ADDITIONAL INFORMATION 21 Date Nature of Operation Number Nominal Issue Share premium Issue price Number Capital Share of shares value of price per (in €) (in €) of shares increase capital issued the share share representing (in €) (in €) (in €) (in €) the share capital May 5, 2017 Share capital 50,000 0.025 3 .275 162,500 163,750 19,590,453 1,250 489,761.33 increase (issuance of ordinary share through exercise of BCE2015-07) May 31, 2017 Share capital 193,800 0.025 0.025 4,845 19,784,253 4,845 494,606.33 increase (issuance of ordinary share through exercise of BCE2013-02) June 27, 2017 Share capital increase 3,750,000 0.025 6.00 22,406,250 22,500,000 23,534,253 93,750 588,356.33 (Euronext PIPE) June 29, 2017 Share capital 7,332 0.025 3.275 23,829 24,012.30 23,541,585 183.3 588,539.63 increase (issuance of ordinary share through exercise of BCE2015-06) June 29, 2017 Share capital 76,120 0.025 0.025 1,903 23,617,705 1,903 590,442.63 increase (issuance of ordinary share through exercise of BCE2013-02) July 3, 2017 Share capital 31,720 0.025 0.025 793.00 23,649,425 793 591,235.63 increase (issuance of ordinary share through exercise of BCE2013-02) July 26, 2017 Share capital increase 291,000 0.025 0.025 7,275 23,940,425 7,275 598,510.63 (issuance of ordinary share through acquisition of AGA (Performance Tranche 1) 2016) July 26, 2017 Share capital 56,000 0.025 0.025 1,400 23,996,425 1,400 599,910.63 increase (issuance of ordinary share through acquisition of AGA2016) September 18, Share capital 237,798 0.025 0.025 5,944.95 24,234,223 5,944.95 605,855.58 2017 increase (issuance of ordinary share through exercise of BCE2013-02) TOTAL 24,234,223 91,273,864.48 97,386,638.20 605,855.58 (1) The company issued 268,235 ordinary shares for the benefit of Novartis in payment for intellectual property rights (see Section 19.1.2, “License Agreement with Novartis Pharma AG”). In compliance with IFRS2, the acquired license was valued at the fair value of issued shares, as assessed by an independent expert, at €1.025 per share. GENSIGHT BIOLOGICS – 2017 Registration Document– 225